Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

RUNX1 is a transcription factor that regulates critical processes in many aspects of
hematopoiesis. RUNX1 is also integral in defining the definitive hematopoietic stem cell. In …

Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently
defined by recurrent cytogenetic abnormalities, including rearrangements involving the core …

Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD)
mutation is an aggressive hematologic malignancy with a grave prognosis. To identify the …

Mutations in codon D816 of the KIT gene represent a recurrent genetic alteration in acute
myeloid leukemia (AML). To clarify the biologic implication of activation loop mutations of the …

Acute myeloid leukemia with t (8; 21)(q22; q22) is characterized by considerable clinical and
biological heterogeneity leading to relapse in up to 40% of patients. We sequenced coding …

Abstract Myeloid cell leukemia-1 (MCL-1) is an essential survival factor for hematopoiesis. In
humans, hematopoietic stem cells (HSCs) express MCL-1 at the highest level in response to …

Internal tandem duplication of the Fms-like tyrosine kinase-3 receptor (FLT3) internal
tandem duplication (ITD) is found in 30% of acute myeloid leukemia (AML) and is associated …

The graft-versus-leukemia effect of allogeneic hematopoietic stem cell transplantation
(HSCT) has shown that the immune system is capable of eradicating acute myeloid …

BACKGROUND: The impact of FMS‐like tyrosine kinase 3 (FLT3) mutations and mutation
burden among cytogenetic subgroups of patients with acute myeloid leukemia (AML) other …